33 results about "Asymptomatic" patented technology

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

Disclosed herein are classifier models, computer implemented systems, machine learning systems and methods thereof for classifying asymptomatic patients into a risk category for having or developing cancer and / or classifying a patient with an increased risk of having or developing cancer into an organ system-based malignancy class membership and / or into a specific cancer class membership.

Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.

The invention discloses a plasma exosome marker of tuberculosis (TB) and application of the plasma exosome marker, and belongs to the field of biomedical diagnosis, the plasma exosome marker comprises hsa-miR-451a, hsa-miR-1908-5p and hsa-miR-1268b, the expression of hsa-miR-451a in the plasma exosome of an active TB patient is up-regulated, and the expression of the hsa-miR-451a and the expression of the hsa-miR-451a and the expression of the hsa-miR-1908-5p are down-regulated. The expression levels of the markers are detected by using a droplet digital PCR technology, and a multinomial logistic regression diagnosis model is constructed based on a detection result. Experiments prove that when the three miRNA combinations are used for distinguishing active tuberculosis from healthy control (HC), the area (AUC) under a working characteristic curve of a subject reaches 0.970; when latent tuberculosis infection (LTBI) is distinguished from a healthy control, AUC is 0.971; and when the secondary miRNA combination of the hsa-miR-451a and the hsa-miR-1268b is used for distinguishing the asymptomatic tuberculosis (aTB) from the healthy control, the AUC is 0.880. The TB early diagnosis accuracy is remarkably improved, the non-invasive advantage is achieved, wide application prospects are achieved in the aspects of preparation of diagnostic reagents and kits, clinical diagnosis, disease monitoring and the like, and global tuberculosis prevention and control work is powerfully promoted.

A system and method for real-time, label-free, in vitro, and cost-effective early disease detection and classification are disclosed. The system integrates multiple spectroscopic techniques, coupled with a firmware¬ controlled terminal gateway and an advanced clinical Al application. It features a sensor unit for sample stability and an actuator to ensure uniform metabolite distribution in liquid samples. The embedded controller dynamically optimizes spectroscopy parameters and processes data in conjunction with the clinical Al application. This enables the precise detection of diseases, including asymptomatic stages. The system's platform-independent architecture ensures adaptability to diverse healthcare settings, such as point-of-care diagnostics and remote environments, while reducing operational complexity and costs. Its innovative design revolutionizes disease monitoring and diagnostics, enabling early intervention.

The application relates to a tracing method for latent period asymptomatic transmission based on an SAIR model, which comprises the following steps: S1, determining a single initial transmission source node in an interpersonal relationship complex network, and transmitting according to the source node according to an SAIR model until a moment t0; S2, randomly selecting a certain number of nodes as observation nodes, and knowing the state of the observation nodes at the moment; S3, screening a candidate source node set in the complex network by using a reverse propagation algorithm according to the state of the partial observation nodes, and the hop distance and the effective distance, and the number of nodes is determined by a sampling method; S4, constructing a dynamic message transmission equation according to the SAIR model, and calculating the probability of the candidate source nodes being in different states at a moment Delta t by using the partial observation nodes; and S5, calculating the likelihood probability of the nodes in the candidate source node set becoming sources by using an average field theory, and the source is the node with the maximum probability. According to the application, the spread of infectious diseases of patients with latent period and asymptomatic can be accurately reflected, and the problem of tracing the source of infection can be solved.

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention belongs to the technical field of molecular biological detection, and relates to a polypeptide for detecting asymptomatic infection of plasmodium vivax malaria and application. The polypeptide for detecting the asymptomatic infection of the malaria of the plasmodium vivax is an amino acid sequence as shown in SEQ ID No.1, or a homologous sequence which is subjected to substitution, deletion or insertion of one or more amino acids or has the sequence similarity greater than 75%. The polypeptide has an amino acid sequence as shown in SEQ ID No. 1. The polypeptide SEQ ID No.1 in the invention specifically detects asymptomatic tertian malaria infection, and can effectively deal with tertian malaria input threats in the Burmese border area. Meanwhile, the polypeptide can be coated in a detection tool of a rapid detection kit, and the tool has the characteristics of portability, high efficiency, low cost and the like, and is suitable for field sample detection in a malaria prevalence area.

To provide molecular signatures of the asymptomatic phase of Alzheimer's disease, methods for diagnosing the asymptomatic phase of Alzheimer's disease in a subject, for predicting the progression of the asymptomatic phase of Alzheimer's disease and for determining a personalized course of treatment in a subject suffering from the asymptomatic phase of Alzheimer's disease, and a computer system comprising a machine learning algorithm trained to diagnose the asymptomatic phase.SOLUTION: The computer system comprises the steps of receiving inputs of the levels, amounts or concentrations of the at least five biomarkers as determined in a sample obtained from the subject, analyzing and transforming the inputs of the levels, amounts or concentrations of the at least five biomarkers by organizing and / or modifying each level, amount or concentration input via a machine learning algorithm to derive a probability score and / or a classification label, and generating an output which is a classification label or a probability score.SELECTED DRAWING: Figure 7

The present invention discloses a marker for detecting lung cancer, its use, and a system. The marker and system can: 1) be used non-invasively for early screening of asymptomatic individuals and prognostic assessment of cancer patients, reducing the risks associated with invasive testing; and 2) offer increased sensitivity and accuracy, enabling real-time monitoring.

Disclosed herein are systems, methods, and devices of detecting illness in presymptomatic and asymptomatic infected persons using wearable sensor technology. In a first embodiment, a method is implemented on a computing device, the method includes receiving first sensor data associated with the person over a first period of time and applying the first sensor data to a multi-variate detection model. The method further includes receiving second sensor data associated with the person over a second period of time and applying the second sensor data to the multi-variate detection model. Further the method includes determining a probability value of the illness in the person using the multi-variate detection model and transmitting the probability value to a user interface (UI).

The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

The present invention relates to early detection of hepatocellular carcinoma. Specifically, the present invention provides methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects into higher risk and lower risk categories for developing hepatocellular carcinoma, and methods for treating and managing subjects suspected of having or at risk for developing hepatocellular carcinoma. While previous work has attempted to address the need for highly sensitive early predictive indicators for hepatocellular carcinoma by evaluating one or more biological factors, none has approached the sensitivity required for a clinically relevant determination of whether a subject, particularly an asymptomatic subject, has the disease. The inventors have discovered that certain combinations of factors meet this need by conferring previously unattainable levels of high accuracy.

The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.

The present invention discloses a method for identifying asymptomatic anthracnose infection in strawberries based on hyperspectral features. The method specifically includes collecting raw spectral feature data and preprocessing the spectral data, screening characteristic wavelengths for detecting asymptomatic anthracnose infection in strawberries, and constructing asymptomatic anthracnose identification models for strawberries using random forests and BP neural networks based on the characteristic wavelengths. The constructed models can non-destructively, quickly, and accurately identify anthracnose-infected strawberry plants during the asymptomatic period. The model constructed based on random forests has a higher recognition rate, while the model constructed using the BP neural network recognition model has higher recognition efficiency and faster speed. In production, an appropriate strawberry disease identification model can be selected according to different needs. The present invention achieves a breakthrough in strawberry disease identification, saves time and the cost of traditional biochemical analysis, improves economic benefits, achieves cost reduction, and conforms to the green and sustainable development of agriculture.

An aortic aneurysm carries increasing risk of rupture with growing aneurysm diameter. This condition is typically asymptomatic, so screening and surveillance are essential. Ultrasound and other imaging methods are employed for such monitoring at high accuracy. However, these methods require an expert and are expensive. Aortic aneurysms are considerably under-detected at present and may become even more under-detected in the future as the disease prevalence increases with societal aging. This disclosure present devices that are convenient in use and cost for aortic aneurysm screening and surveillance.

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early stages by cardiologists remain a challenge. Here, the inventors have measured baseline sTREM-1 (triggering receptor expressed on myeloid cells-1) in 10,000 initially healthy participants without prevalent cardiovascular disease (CVD) from the Paris Prospective Study 3 (PPS3). They have quantified the association and predictive value of baseline sTREM-1 for incident CVD events over 10 years of follow-up. The analysis reveals strong, significant and independent association with incident CVD events combined and its subtypes (coronary heart disease, stroke, peripheral artery diseases, and heart failure). Furthermore, adding sTREM-1 to existing risk prediction algorithms such as SCORE2 or the US pooled risk equation improved the discrimination capacity of these models in a significant and more importantly in a clinically meaningful manner, including among those at moderate CVD risk. Furthermore, the inventors have examined CVD events such as aneurysm, arrythmias and thromboembolic events. Given the ongoing development of pharmacological molecules blocking blood sTREM-1, the inventors believe these findings support future intervention trials testing to which extent sTREM-1 could be a relevant target for the primary prevention of CVD in the general population.

The present invention provides methods for the assessment of an adnexal mass predetermined to be benign or asymptomatic (e.g., asymptomatic or benign adnexal mass) in a variety of subjects (e.g., pre- and post-menopausal women). In particular, the present invention provides methods for determining the malignancy risk of ovarian tumors in selected subjects (e.g., benign or indeterminate risk).

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

This invention provides the application of human protocadherin 18 (PCDH18) as a biomarker in the preparation of products for the diagnosis, auxiliary diagnosis, or progression prediction of antiphospholipid syndrome (APS), belonging to the field of in vitro diagnostic technology. In this invention, detecting serum PCDH18 levels in patients is helpful in diagnosing APS and is specific to this disease, and can be used to differentiate APS from other connective tissue diseases. Furthermore, APS patients have higher serum PCDH18 levels compared to asymptomatic aPL-positive patients. Therefore, PCDH18 testing in aPL-positive individuals is helpful for the early diagnosis and intervention of APS. Additionally, serum PCDH18 levels in OAPS patients are significantly higher than in TAPS patients, suggesting that PCDH18 can serve as a biomarker for differentiating or assisting in the differentiation of TAPS and OAPS.

A viral exposure signature (VES) that can identify early stage, pre-symptomatic hepatocellular carcinoma (HCC) among at-risk patients is described. The VES was developed using serological profiling and synthetic virome technology to identify unique viral peptide epitopes corresponding to 61 viral species. Methods of identifying a subject with early stage (pre-symptomatic) HCC using the VES are described.

The invention discloses a marker and a probe composition for early diagnosis of gastric cancer and application of the marker and the probe composition. The marker is an ST8SIA1 gene and / or an SPAG4 gene. According to the present invention, with the application of the marker, the methylation state of the gene can be sensitively and specifically detected so as to be used for the detection of the DNA of the plasma sample of the gastric cancer patient, and the composition is used for the screening of the asymptomatic population in the non-invasive manner so as to reduce the harm caused by the invasive detection, and further improve the detection efficiency. The composition has higher sensitivity and accuracy, and can realize real-time monitoring.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.

The invention provides a method and a system for predicting the growth risk of accidental asymptomatic meningioma. The method comprises the following steps: acquiring baseline clinical data, iconomic semantic feature data and iconomic feature data of a patient suffering from accidental asymptomatic meningioma; dividing the patient queue into a training set, a verification set and a test set, screening independent prediction factors significantly related to tumor growth, training a random survival forest model based on the training set, and performing optimization and verification in the verification set and the test set to generate an optimal model for predicting the individualized time-dependent growth risk; and inputting related data of a patient to be predicted into the optimal model, and outputting meningioma growth risk assessment results at different time points in the future. According to the invention, the technical problem that a patient with primary asymptomatic meningioma lacks an individualized natural growth trend prediction tool is solved.

The invention provides a composition for detecting vascular senescence and carotid arteriosclerosis as well as application and a kit thereof, and relates to the technical field of biology, the composition for detecting vascular senescence and carotid arteriosclerosis comprises a forward primer and a reverse primer of circular RNA (Ribonucleic Acid) 0006222 in plasma endothelial cell membrane particles, can detect circular RNA 0006222 in in-vitro plasma endothelial cell membrane particles, and can detect the circular RNA 0006222 in in-vitro plasma endothelial cell membrane particles. The circular RNA 0006222 in plasma endothelial cell membrane particles is used as a biomarker of vascular aging and CAS, the plasma EMVs-circRNA 0006222 has the sensitivity of 76.8% and 75.8% and the specificity of 54.3% and 73.2% for distinguishing the areas under curves of vascular aging and CAS respectively, has good sensitivity and specificity, and can accurately identify the progress of vascular aging and carotid arteriosclerosis in an early asymptomatic stage.

The present application relates to the technical field of infectious disease monitoring, and specifically relates to an infectious disease monitoring method for international ship crew, comprising: calibrating all crew members on the ship to be in a healthy state during a calibration period; collecting the body temperature and SDNN data of all crew members during the calibration period through a monitoring bracelet, and establishing a physiological baseline database of the ship; judging the physiological index abnormality degree of individual crew members; calculating the group abnormality degree according to the physiological index abnormality degree of individual crew members; calculating a risk index according to the group abnormality degree; setting an early warning value, and comparing the risk index with the early warning value; the present application takes the ship as a monitoring unit, adopts individual and group double-index joint determination, and reduces the false alarm rate; as long as the overall biological rhythm of the whole ship appears "resonance", the body temperature and / or SDNN of most people simultaneously rise or fall, even if the number of abnormal people is 0, the existence of the pathogenic risk can be determined, the weak group signal caused by asymptomatic infected persons can be captured, and the early warning effect is improved.

The invention discloses a marker and a probe composition for ovarian cancer and application of the marker and the probe composition. The marker is LYPLAL1-DT. According to the present invention, with the application of the marker, the methylation state of the gene can be sensitively and specifically detected so as to be used for the detection of the peripheral blood free DNA, and the composition is used for the screening of the asymptomatic population in the non-invasive manner so as to reduce the harm caused by the invasive detection; the composition has higher sensitivity and accuracy, and can realize real-time monitoring.